The ASCO Certified Task Force approved 26 OneOncology Treatment Pathways as appropriate for use in ASCO Certified in 2024. OneOncology’s 26 unique oncology and hematology pathways mark only the fifth available pathway program reviewed and determined appropriate for use in this prestigious certification program.

OneOncology takes a physician-led approach to pathway development. Edward Arrowsmith, MD, Medical Director of OneOncology’s Pathways Program, and physician experts from OneCouncil’s Disease Groups (gastrointestinal, genitourinary, breast, lung, and hematology) and other disease subject matter physician experts (gynecology, head, and neck) lead in authoring OneOncology pathways. OneOncology’s pathways are concordant with many nationally recognized evidence-based guidelines, list various treatment options ensuring they are all-encompassing, and include clinical trials when available for a specific cancer setting. The pathways are published inside OneOncology’s clinical decision support tool and are utilized by more than 80 percent of physician orders across the network.

Developing pathways begins with the Pharmacy and Therapeutics (P&T) Committee of an all-physician body called OneCouncil that reviews and approves all new indications or new molecular entities and then authors a drug monograph. Once the monograph is approved by the P&T Committee, the newly approved agent is incorporated in draft form into the appropriate pathway and presented to the appropriate OneCouncil Disease Group. Based on efficacy and the adverse event profile of the new agent compared with other treatment options, Disease Group members decide if and where it should be added to the pathway.

Pathways are reviewed and updated regularly by OneOncology experts when data is presented at nationally recognized meetings or in peer-reviewed journals. Each pathway is broken out by appropriate stage and treatment options by stage, including neoadjuvant, adjuvant, recurrent, locally advanced, and metastatic treatment settings, and have potential treatment options clearly listed.

OneOncology’s treatment pathways increase appropriate first-line treatment, based on genomic testing and biomarkers, while reducing adverse events experienced by patients due to standardized regimens and appropriate supportive care. Being recognized by ASCO Certified demonstrates to physician partners the OneOncology Treatment Pathways meet ASCO Criteria for High Quality Clinical Pathways in Oncology.